Fulcrum Therapeutics, Inc. $FULC Shares Acquired by Siren L.L.C.

Siren L.L.C. increased its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 20.5% during the 1st quarter, HoldingsChannel reports. The firm owned 2,350,000 shares of the company’s stock after acquiring an additional 400,000 shares during the period. Siren L.L.C.’s holdings in Fulcrum Therapeutics were worth $18,024,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in FULC. Cubist Systematic Strategies LLC bought a new position in Fulcrum Therapeutics during the 1st quarter worth $164,000. Jane Street Group LLC lifted its stake in Fulcrum Therapeutics by 62.1% in the first quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock valued at $339,000 after buying an additional 45,157 shares during the last quarter. Creative Planning bought a new stake in Fulcrum Therapeutics in the second quarter valued at $117,000. Legal & General Group Plc boosted its holdings in shares of Fulcrum Therapeutics by 230.2% during the second quarter. Legal & General Group Plc now owns 17,461 shares of the company’s stock valued at $120,000 after acquiring an additional 12,173 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Fulcrum Therapeutics by 7.0% during the second quarter. American Century Companies Inc. now owns 132,349 shares of the company’s stock valued at $911,000 after acquiring an additional 8,638 shares during the period. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

NASDAQ:FULC opened at $3.76 on Friday. The stock has a market cap of $250.53 million, a price-to-earnings ratio of -3.27 and a beta of 3.01. Fulcrum Therapeutics, Inc. has a 1 year low of $2.83 and a 1 year high of $15.74. The business has a fifty day moving average of $4.31 and a 200-day moving average of $7.18.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.06. On average, equities research analysts predict that Fulcrum Therapeutics, Inc. will post -0.67 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Stifel Nicolaus downgraded shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. Piper Sandler lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Tuesday, June 2nd. Wall Street Zen upgraded shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Reduce” and a consensus price target of $8.20.

Insider Buying and Selling

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $3.65, for a total transaction of $65,700.00. Following the transaction, the director owned 10,927 shares of the company’s stock, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.30% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.